Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 500
- Registration Number
- NCT00002719
- Locations
- ๐ฎ๐น
Azienda Policlinico Umberto Primo, Rome, Italy
Combination Chemotherapy in Treating Children With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT00002590
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธChildren's Hospital of Columbus, Columbus, Ohio, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Robert H. Lurie Cancer Center
- Registration Number
- NCT00004903
- Locations
- ๐บ๐ธ
University of Chicago Cancer Research Center, Chicago, Illinois, United States
๐บ๐ธRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004878
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Rush University Medical Center
- Registration Number
- NCT00003407
- Locations
- ๐บ๐ธ
Cook County Hospital, Chicago, Illinois, United States
๐บ๐ธAngelo P. Creticos, M.D. Cancer Center, Chicago, Illinois, United States
๐บ๐ธRush Cancer Institute, Chicago, Illinois, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Drexel University College of Medicine
- Registration Number
- NCT00003619
- Locations
- ๐บ๐ธ
Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธMedical College of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT00003783
- Locations
- ๐บ๐ธ
West Virginia University Medical School, Charleston Division, Charleston, West Virginia, United States
๐บ๐ธSimmons Cancer Center - Dallas, Dallas, Texas, United States
๐บ๐ธArizona Cancer Center, Tucson, Arizona, United States
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 23
- Registration Number
- NCT00081822
- Locations
- ๐บ๐ธ
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
๐บ๐ธThe University of Nebraska, Omaha, Nebraska, United States
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00002800
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002534
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.